



GOVERNOR'S OFFICE OF
BUDGET AND PROGRAM PLANNING

Fiscal Note 2027 Biennium

Bill#/Title: **SB0317.01: Prohibit health insurers from performing prior authorization on psychiatric drugs in shortage or discontinued**

Primary Sponsor: Dennis Lenz Status: As Introduced

☐ Included in the Executive Budget ☐ Needs to be included in HB 2 ☐ Significant Local Gov Impact
☐ Significant Long-Term Impacts ☐ Technical Concerns ☐ Dedicated Revenue Form Attached

FISCAL SUMMARY

	<u>FY 2026 Difference</u>	<u>FY 2027 Difference</u>	<u>FY 2028 Difference</u>	<u>FY 2029 Difference</u>
Expenditures				
General Fund (01)	\$0	\$0	\$0	\$0
Revenues				
General Fund (01)	\$0	\$0	\$0	\$0
Net Impact	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>
General Fund Balance	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>

Description of fiscal impact

SB 317 prohibits health insurance issuers from performing a prior authorization on psychiatric drugs that are in shortage or discontinued. Although the requirements in this bill may cause an increase in enforcement on the part of the State Auditor's Office, these enforcement activities will be performed with the office's existing staff.

FISCAL ANALYSIS


Assumptions

Department of Administration

1. There is no fiscal impact to the Department of Administration from SB 317. The removal of prior authorizations will affect Title 33 entities, not the State Health Plan, which is Title 2.

State Auditor's Office

2. Although this requirement may cause an increase in enforcement on the part of the State Auditor's Office, the office can cover the additional enforcement activities with existing staff.



Sponsor's Initials

2/27

Date



Budget Director's Initials

2/26/2025

Date